KPV for Inflammation and Tissue Repair — Performance & Recovery
Anti-inflammatory tripeptide (α-MSH fragment) with PRECLINICAL-ONLY evidence for reducing inflammation. NO human trials exist.
Overview
KPV (Lys-Pro-Val) is a tripeptide derived from alpha-MSH with potent anti-inflammatory properties. CRITICAL EVIDENCE STATUS: NO FDA approval. ZERO published human clinical trials. Strong PRECLINICAL evidence in animal models only (particularly IBD mouse studies). Well-understood mechanism: NF-κB inhibition via PepT1 transport (not melanocortin receptors). No established human dosing guidelines. No long-term human safety data. Available only through compounding/research channels. Like BPC-157 and TB-500, KPV exists in regulatory gray area - promising animal data but NOT an approved pharmaceutical. Anyone using KPV is participating in uncontrolled experimentation. Also shows antimicrobial activity against S. aureus and C. albicans in vitro.
Indications
- Chronic inflammation reduction (based on animal studies only)
- Inflammatory bowel conditions (preclinical mouse data)
- Joint inflammation and pain (extrapolated, no human evidence)
Mechanism of Action
Persistent inflammation from injury, inflammatory bowel disease, or joint conditions causes tissue damage
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| KPV (compounded) | 500-1000 mcg | Once or twice daily | DERIVED FROM ANIMAL DATA - no human dosing guidelines exist |
Evidence Grade
GRADE D
Safety & Contraindications
- CRITICAL: NO FDA approval; NO human clinical trials exist
- All dosing derived from animal studies - no human dosing guidelines
- No long-term human safety data available
- Available only via compounding/research channels (no FDA quality oversight)
- Pediatric, elderly, and immunocompromised populations NOT studied
- Generally well-tolerated in available preclinical data
- Use of KPV constitutes uncontrolled human experimentation